Narsale Aditi, Davies Joanna D
San Diego Biomedical Research Institute, 10865 Road to the Cure, Suite 100, San Diego, CA, 92121, USA.
Curr Diab Rep. 2017 Aug;17(8):61. doi: 10.1007/s11892-017-0889-9.
Therapies that target beta-cell antigen-specific T cells subsets have not been as successful in patients with type 1 diabetes as in mice. This might be explained by complexities in the repertoire of beta-cell antigen-specific T cells and the variety of T cell subsets involved in type 1 diabetes development in human.
T cells that infiltrate islets of people with type 1 diabetes (i) react towards known islet cell antigens but also unknown antigens, (ii) differ from one patient to another, and (iii) are also present in the circulation, but not in the islets, of healthy people. Moreover, several circulating memory T cell subsets not recognized as relevant in mouse are significantly associated with clinical outcome. A more detailed understanding of the specificity, phenotype, and function of T cells that are associated with defined clinical outcomes might identify new pathways for therapeutic intervention.
靶向β细胞抗原特异性T细胞亚群的疗法在1型糖尿病患者中的效果不如在小鼠中那样显著。这可能是由于β细胞抗原特异性T细胞库的复杂性以及人类1型糖尿病发病过程中涉及的多种T细胞亚群所致。
浸润1型糖尿病患者胰岛的T细胞(i)对已知胰岛细胞抗原以及未知抗原产生反应,(ii)在不同患者之间存在差异,并且(iii)也存在于健康人的循环系统中,但不存在于胰岛中。此外,几种在小鼠中未被认为相关的循环记忆T细胞亚群与临床结局显著相关。对与特定临床结局相关的T细胞的特异性、表型和功能有更详细的了解,可能会发现新的治疗干预途径。